Central regions | Technology & innovation

NewVac pushes for new-fangled cancer immunotherapy

2 Dec '11
Russias innovative biotech company and a Skolkovo resident, NewVac, is developing cutting-edge cancer immunotherapy technology and has recently completed some tests, Rusnanonet Russian National Nanotech Network reports.

The company is reportedly working on new low-molecular compounds that could be used as co-adjuvant to dramatically improve the effect of therapeutic antitumoral vaccines, and moving to clinical trials of new cancer immunotherapy techniques.

The fundamental idea of blocking protective mechanisms cancer cells employ against the human bodys immune response is said to have been first formulated by Dr. Mikhail Sitkovsky from the New England Inflammation and Tissue Protection Institute (NEITPI), Boston, the U.S.

Earlier this year NewVac scientists developed and tested a number of new synthetic A2A inhibitors for use with oncovaccines and are assumed to have patented their IP.

The work done has reportedly resulted in the development of clinical trials protocols. The Russian researchers have plans to perform clinical trials over the course of next year to see if the new cancer treatment method is safe and efficient.

According to NewVac CEO Sergei Bugrov, the company is supported by the Skolkovo Foundation. NewVacs goal is the creation of a Russian-based innovative, world-class biomed platform for cancer treatment centered on immunotherapy, personalized medicine and other modern approaches.

NewVac is an innovative biomed company located in the town of Khimki just outside Moscow. It is a subsidiary of Russias largest private biomed R&D center, KhimRar.
Publish in Twitter
Write to Facebook
Google Buzz
Write to LiveJournal
Show in MM
Share MK
COMMENT ON THIS STORY
Find Related Content

Locations: Khimki

Latest News: Central regions
17 Oct '17 | Finance, business | Technology & innovation
13 Oct '17 | Finance, business | Retail, FMCG
12 Oct '17 | Finance, business | Technology & innovation
 

Feature stories

7 Sep '17
26 Jul '17
Scientists at Tomsk Polytechnic (TPU) in Siberia have...
20 Jun '17
In regions most of European Russians will hardly ever...
Search (News archive - 21174)
Advertising
Global_Entrepreneurship_Monitor
Advertising
Marchmont News

Latest News

20 Oct '17
Infectex, a Russian biomed company, is readying for...
19 Oct '17
Russian scientists in partnership with their Korean...
18 Oct '17
Scientists at the Novosibirsk-based Boreskov...

Most read stories from last week

20 Oct '17
Infectex, a Russian biomed company, is readying for...